Several brokerages have updated their recommendations and price targets on shares of Chemed Corp. (NYSE: CHE) in the last few weeks:

  • 9/13/2017 – Chemed Corp. was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Following its promising second quarter 2017 performance, Chemed has been observed to trade above the broader industry over the past six months. Also, the guidance raise backed by  the company's expectations of significant gains from its Roto-Rooter business buoys optimism. This business has witnessed consistent growth over the recent past banking on strong performance within its core plumbing and drain cleaning service segments, as well as solid growth in water restoration. However, headwinds like reimbursement related issues, seasonality in business, a competitive landscape and dependence on government mandate pose challenges for Chemed.  Moreover, over 90% of VITAS’ revenues consist of payments from the Medicare and Medicaid programs which further intensify pricing pressure. Also, a tweaked guidance for Medicare Cap billing limitations raises concern.”
  • 9/6/2017 – Chemed Corp. was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Over the past six months, Chemed has been trading above the broader industry. Chemed’s last reported second-quarter 2017 performance was quite promising with the bottom line significantly improving on a year-over-year basis. Moreover, encouraging revenue growth and the raised guidance for 2017 are indicative of brighter prospects. In fact, the guidance raise was backed by the company expectations of significant gains from its Roto-Rooter business. Notably, the improvement in average net Medicare reimbursement rate and increase in average daily census are also impressive. However, headwinds like reimbursement related issues, seasonality in business, a competitive landscape and dependence on government mandate pose challenges for Chemed.  Also, a tweaked guidance for Medicare Cap billing limitations raises concern.”
  • 9/1/2017 – Chemed Corp. had its “hold” rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $209.00 price target on the stock.
  • 8/28/2017 – Chemed Corp. is now covered by analysts at KeyCorp. They set a “sector weight” rating on the stock.
  • 8/23/2017 – Chemed Corp. was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $213.00 price target on the stock. According to Zacks, “Over the past six months, Chemed has been trading above the broader industry. Chemed’s last reported second-quarter 2017 performance was quite promising with the bottom line significantly improving on a year-over-year basis. Moreover, encouraging revenue growth and the raised guidance for 2017 are indicative of brighter prospects. In fact, the guidance raise was backed by the company expectations of significant gains from its Roto-Rooter business. Notably, the improvement in average net Medicare reimbursement rate and increase in average daily census are also impressive. However, headwinds like reimbursement related issues, seasonality in business, a competitive landscape and dependence on government mandate pose challenges for Chemed.  Also, a tweaked guidance for Medicare Cap billing limitations raises concern.”
  • 8/22/2017 – Chemed Corp. was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Over the past six months, Chemed has been trading above the broader industry. Chemed’s last reported second-quarter 2017 performance was quite promising with the bottom line significantly improving on a year-over-year basis. Moreover, encouraging revenue growth and the raised guidance for 2017 are indicative of brighter prospects. In fact, the guidance raise was backed by the company expectations of significant gains from its Roto-Rooter business. Notably, the improvement in average net Medicare reimbursement rate and increase in average daily census are also impressive. However, headwinds like reimbursement related issues, seasonality in business, a competitive landscape and dependence on government mandate pose challenges for Chemed.  Also, a tweaked guidance for Medicare Cap billing limitations raises concern.”
  • 8/2/2017 – Chemed Corp. was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 7/31/2017 – Chemed Corp. had its “hold” rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $209.00 price target on the stock.
  • 7/28/2017 – Chemed Corp. was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $226.00 price target on the stock. According to Zacks, “Chemed’s second-quarter 2017 performance was quite promising with the bottom line significantly improving on a year-over-year basis. Moreover, encouraging revenue growth and the raised guidance for 2017 are indicative of brighter prospects. In fact, the guidance raise was backed by the company expectations of significant gains from its Roto-Rooter business. Also, over the past six months, Chemed has been trading above the broader industry. Notably, the improvement in average net Medicare reimbursement rate and increase in average daily census are also impressive. However, headwinds like reimbursement related issues, seasonality in business, a competitive landscape and dependence on government mandate pose challenges for Chemed. Also, a tweaked guidance for Medicare Cap billing limitations raises concern.”
  • 7/27/2017 – Chemed Corp. had its price target raised by analysts at Oppenheimer Holdings, Inc. from $200.00 to $220.00. They now have an “outperform” rating on the stock.
  • 7/25/2017 – Chemed Corp. was downgraded by analysts at TheStreet from a “b+” rating to a “c+” rating.

Shares of Chemed Corp. (NYSE CHE) opened at 193.32 on Friday. Chemed Corp. has a 52-week low of $132.92 and a 52-week high of $216.01. The stock has a 50 day moving average of $193.87 and a 200-day moving average of $195.60. The stock has a market capitalization of $3.09 billion, a price-to-earnings ratio of 47.96 and a beta of 1.14.

Chemed Corp. (NYSE:CHE) last issued its quarterly earnings results on Tuesday, July 25th. The company reported $2.15 EPS for the quarter, topping the Zacks’ consensus estimate of $1.89 by $0.26. The business had revenue of $415.06 million for the quarter, compared to analyst estimates of $407.56 million. Chemed Corp. had a return on equity of 26.18% and a net margin of 4.16%. Chemed Corp.’s quarterly revenue was up 6.3% compared to the same quarter last year. During the same period last year, the company posted $1.80 earnings per share. On average, equities research analysts predict that Chemed Corp. will post $8.21 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Friday, September 1st. Investors of record on Monday, August 14th were issued a dividend of $0.28 per share. This is a positive change from Chemed Corp.’s previous quarterly dividend of $0.26. This represents a $1.12 dividend on an annualized basis and a yield of 0.58%. The ex-dividend date was Thursday, August 10th. Chemed Corp.’s dividend payout ratio (DPR) is 28.07%.

In other Chemed Corp. news, Director George J. Walsh III purchased 1,000 shares of the company’s stock in a transaction that occurred on Monday, June 26th. The shares were acquired at an average cost of $204.56 per share, for a total transaction of $204,560.00. Following the completion of the acquisition, the director now owns 7,908 shares of the company’s stock, valued at approximately $1,617,660.48. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Kevin J. Mcnamara sold 15,000 shares of Chemed Corp. stock in a transaction on Friday, July 28th. The stock was sold at an average price of $201.16, for a total value of $3,017,400.00. Following the sale, the insider now owns 173,801 shares in the company, valued at $34,961,809.16. The disclosure for this sale can be found here. Company insiders own 5.32% of the company’s stock.

Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.

Receive News & Ratings for Chemed Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed Corp and related companies with MarketBeat.com's FREE daily email newsletter.